Quantum-Si to Present at the 2024 American Society of Human Genetics Annual Meeting
Quantum-Si (Nasdaq: QSI) announced its participation in the 2024 American Society of Human Genetics Annual Meeting, where it will present on Next-Generation Protein Sequencing (NGPS) technology. The presentation, titled 'From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si's Next-Generation Protein Sequencing Technology,' will feature Dr. Meredith Carpenter and Dr. Colette Felton from UC Santa Cruz.
The presentation will demonstrate how NGPS technology validates transcriptomics predictions by confirming protein presence, abundance, and modifications. Dr. Felton will discuss using long-read RNA sequencing to detect variants in cancer genes and applying NGPS for protein-level validation. Quantum-Si will be available at booth #465 during ASHG 2024.
Quantum-Si (Nasdaq: QSI) ha annunciato la sua partecipazione al 2024 American Society of Human Genetics Annual Meeting, dove presenterà la tecnologia Next-Generation Protein Sequencing (NGPS). La presentazione, intitolata 'Dalla Predizione alla Proteina: Validazione dei Dati Transcriptomici con la Tecnologia di Sequenziamento delle Proteine di Nuova Generazione di Quantum-Si', vedrà la partecipazione della Dott.ssa Meredith Carpenter e della Dott.ssa Colette Felton dell'UC Santa Cruz.
La presentazione dimostrerà come la tecnologia NGPS convalida le previsioni transcriptomiche confermando la presenza, l'abbondanza e le modifiche delle proteine. La Dott.ssa Felton discuterà dell'uso del sequenziamento RNA a lettura lunga per rilevare varianti nei geni del cancro e dell'applicazione dell'NGPS per la validazione a livello proteico. Quantum-Si sarà disponibile allo stand n. 465 durante l'ASHG 2024.
Quantum-Si (Nasdaq: QSI) anunció su participación en la reunión anual de la Sociedad Americana de Genética Humana 2024, donde presentará la tecnología de Secuenciación de Proteínas de Nueva Generación (NGPS). La presentación, titulada 'De la Predicción a la Proteína: Validando Datos de Transcriptómica con la Tecnología de Secuenciación de Proteínas de Nueva Generación de Quantum-Si', contará con la participación de la Dra. Meredith Carpenter y la Dra. Colette Felton de UC Santa Cruz.
La presentación demostrará cómo la tecnología NGPS valida las predicciones transcriptómicas al confirmar la presencia, abundancia y modificaciones de las proteínas. La Dra. Felton discutirá el uso de la secuenciación de RNA de lectura larga para detectar variantes en genes del cáncer y la aplicación de NGPS para validación a nivel proteico. Quantum-Si estará disponible en el stand #465 durante el ASHG 2024.
Quantum-Si (Nasdaq: QSI)는 2024년 미국 인간 유전학회 연례 회의에 참여할 것이라고 발표하며 차세대 단백질 시퀀싱(NGPS) 기술에 대해 발표할 예정입니다. '예측에서 단백질까지: Quantum-Si의 차세대 단백질 시퀀싱 기술로 전사체 데이터를 검증하기'라는 제목의 발표에 UC 샌타크루즈의 Meredith Carpenter 박사와 Colette Felton 박사가 참여할 것입니다.
이 발표는 NGPS 기술이 단백질의 존재, 양 및 변화를 확인함으로써 전사체 예측을 확인하는 방법을 시연할 것입니다. Felton 박사는 암 유전자에서 변이를 감지하기 위한 장시간 RNA 시퀀싱 사용과 단백질 수준 검증을 위한 NGPS 적용에 대해 논의할 것입니다. Quantum-Si는 ASHG 2024 기간 동안 부스 #465에서 만날 수 있습니다.
Quantum-Si (Nasdaq: QSI) a annoncé sa participation à la réunion annuelle de la Société Américaine de Génétique Humaine 2024, où elle présentera la technologie de Séquençage des Protéines de Nouvelle Génération (NGPS). La présentation, intitulée 'De la Prédiction à la Protéine : Validation des Données Transcriptomiques avec la Technologie de Séquençage des Protéines de Nouvelle Génération de Quantum-Si', sera animée par Dr Meredith Carpenter et Dr Colette Felton de l'UC Santa Cruz.
Cette présentation démontrera comment la technologie NGPS valide les prédictions transcriptomiques en confirmant la présence, l'abondance et les modifications des protéines. Dr Felton discutera de l'utilisation du séquençage d'ARN à longue lecture pour détecter des variants dans les gènes du cancer et de l'application de NGPS pour la validation au niveau des protéines. Quantum-Si sera présent au stand n°465 lors de l'ASHG 2024.
Quantum-Si (Nasdaq: QSI) gab seine Teilnahme am jährlichen Treffen der American Society of Human Genetics 2024 bekannt, wo es die Technologie Next-Generation Protein Sequencing (NGPS) präsentieren wird. Die Präsentation mit dem Titel 'Von der Vorhersage zum Protein: Validierung von Transkriptomdaten mit der Next-Generation Protein Sequencing Technologie von Quantum-Si' wird von Dr. Meredith Carpenter und Dr. Colette Felton von der UC Santa Cruz gehalten.
Die Präsentation wird zeigen, wie die NGPS-Technologie Transkriptom-Vorhersagen validiert, indem sie die Anwesenheit, Fülle und Modifikationen von Proteinen bestätigt. Dr. Felton wird die Verwendung von Langlese-RNA-Sequenzierung zur Entdeckung von Varianten in Krebsgenen und die Anwendung von NGPS zur Validierung auf Proteinebene erörtern. Quantum-Si wird während der ASHG 2024 am Stand #465 verfügbar sein.
- None.
- None.
"From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si’s Next-Generation Protein Sequencing™ Technology"
The presentation, titled “From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si’s Next-Generation Protein Sequencing Technology,” features insights from both Quantum-Si and a leading academic researcher on the intersection of transcriptomics and proteomics.
Quantum-Si’s Head of Scientific Affairs, Dr. Meredith Carpenter, will be joined by Dr. Colette Felton, a postdoctoral scholar from the Angela Brooks lab at the University of
"Genomic and transcriptomic data are powerful tools for understanding genetic variation and RNA expression patterns, but they often fall short in capturing the full complexity of the picture at the protein level," said Dr. Carpenter. “NGPS bridges this critical gap, directly analyzing proteoforms predicted by RNA sequencing to give researchers a reliable, high-resolution view of protein diversity and insight into functional impact.”
In her portion of the presentation, Dr. Felton will highlight recent advances in using long-read RNA sequencing to detect novel variants, such as single nucleotide variants (SNVs), insertions, deletions, and gene fusions, in cancer genes. She will then discuss how she is applying NGPS to validate the presence of these variants at the protein level, which is crucial for understanding their role in disease, and will review recent data demonstrating the ability of NGPS to detect proteoform-specific variation.
"Our NGPS technology empowers researchers to confirm the presence of predicted proteoforms directly at the protein level, complementing the innovative discoveries in transcriptomics," said Jeff Hawkins, CEO of Quantum-Si. "Our collaboration with UC Santa Cruz reflects our commitment to advancing multi-omics research through impactful partnerships that drive scientific progress."
To meet the team at ASHG 2024, attendees can visit booth #465.
For more information on Quantum-Si’s technology and research applications, please visit The Protein Sequencing Company™ | Quantum-Si
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030134351/en/
Investor
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What will Quantum-Si (QSI) present at ASHG 2024?
How does Quantum-Si's NGPS technology complement RNA sequencing?
Who are the key speakers at Quantum-Si's ASHG 2024 presentation?
Where can attendees find Quantum-Si at ASHG 2024?
